Cytek Biosciences (CTKB) Change in Accured Expenses (2020 - 2026)

Cytek Biosciences has reported Change in Accured Expenses for 7 years, with the latest figure at -$3.9 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses fell 83.4% year-over-year to -$3.9 million; the trailing twelve-month figure through Mar 2026 stood at $2.2 million (up 32.51% YoY), and the FY2025 full-year result was $4.0 million, up 585.92% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$3.9 million, down from $4.7 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $5.6 million in Q3 2024, with the low at -$4.8 million in Q2 2024.
• Historically, Change in Accured Expenses has averaged $438941.2 across 5 years, with a median of $335000.0 in 2023.
• The largest YoY upside for Change in Accured Expenses was 2368.91% in 2024 against a maximum downside of 360.86% in 2024.
• Cytek Biosciences' Change in Accured Expenses stood at $4.6 million in 2022, then sank by 97.44% to $119000.0 in 2023, then jumped by 2368.91% to $2.9 million in 2024, then surged by 60.28% to $4.7 million in 2025, then tumbled by 182.61% to -$3.9 million in 2026.
• The last three Change in Accured Expenses figures came in at -$3.9 million (Q1 2026), $4.7 million (Q4 2025), and -$1.4 million (Q3 2025), per Business Quant data.